达格列净与利格列汀在胰岛素控制不佳的肥胖型T2DM患者中的降糖效果比较

doi:10.3969/j.issn.1001-8131.2024.03.014

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (381 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the hypoglycemic effect of daggliptin and liggliptin in obese T2DM patients with poor insulin control. Methods A total of 74 patients diagnosed with obese T2DM were selected as the study subjects.They were randomly divided into dagliazine group and lipliptin group,with 37 cases in each group.Both groups were treated with dagliazine or lipliptin,respectively.Fasting blood glucose（FBG）,postprandial 2h blood glucose（2h PBG）and glycosylated hemoglobin（HbA1c）were compared between the two groups.Body mass index（BMI）,waist circumference（WC）and body FAT percentage（FAT）were compared between the two groups. Results After intervention,the level of lipid metabolism in both groups decreased compared with that before intervention.However,the FBG（8.31±; 0.71）,2h PBG（9.13±; 1.63）and HbA1c（8.86±; 0.82）in Ligliptin group were significantly better than those in Dagliegine group（9.78±; 0.91）,（10.37±; 1.94）and（8.11±; 0.45）.Obesity indexes in both groups were improved,but the decreasing trend in the lipliptin group was better than that in the dagliegine group,with statistical significance（P<; 0.05）. Conclusion Daggliptin and liggliptin can effectively control blood sugar and reduce the weight of obese T2DM patients with poor insulin control,which is worthy of clinical application.

Key words： Daglijing Linagliptin insulin Obese T2DM

Received: 03 June 2023

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Liu Xiaoyan
	Liu Fang
	Xu Fengmei

Cite this article:

Liu Xiaoyan,Liu Fang,Xu Fengmei. T2DM Comparison of the Hypoglycemic Effect of Daggliptin and Liggliptin in Obese T2DM Patients with Poor Insulin Control[J]. journal1, 2024, 44(3): 41-43.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2024.03.014 OR http://www.hrbyybjb.org.cn/EN/Y2024/V44/I3/41

[1] Kanaley JA,Colberg SR,Corcoran MH,et al.Exercise/Physical Activity in Individuals with Type 2 Diabetes:A Consensus Statement from the American College of Sports Medicine[J].Med Sci Sports Exerc.2022,54(2):353-368.
[2] 辛宁,贾中春,卫建立.利格列汀与达格列净对双胍类/磺脲类控制不佳T2DM患者糖脂代谢的影响观察[J].医药论坛杂志,2020,41(8):126-129.
[3] 杨锡仪,周全,黄绍鹏,等.达格列净和利格列汀治疗超重或肥胖2型糖尿病伴微量白蛋白尿患者的效果比较[J].中国当代医药,2021,28(24):62-65.
[4] 高芳芳,张萍,钟兴,等.达格列净对血糖控制不佳的2型糖尿病患者血糖波动的影响[J].山东医药,2020,60(014):48-50.
[5] Ortiz-Martínez M,González-González M,Martagón AJ,et al.Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus[J].Curr Diab Rep2022 ,22(3):95-115.
[6] 黄建青,陈阳,童艳,等.达格列净联合胰岛素治疗超重/肥胖及胰岛功能受损且血糖控制不佳的2型糖尿病患者的效果[J].中外医学研究,2021,19(12):8-11.
[7] Courcoulas AP,Gallagher JW,Neiberg RH,et al.Bariatric Surgery vs Lifestyle Intervention for Diabetes Treatment:5-Year Outcomes From a Randomized Trial[J].J Clin Endocrinol Metab.2020,105(3):866-876.
[8] 胡玉娟,王尉,徐延德.达格列净对血糖控制不佳的2型糖尿病患者血糖波动的影响[J].糖尿病新世界,2022,25(11):21-25.
[9] 张东铭,崔婷婷,张锦,等.达格列净与利格列汀对2型糖尿病患者代谢指标及PR间期的影响研究[J].中国全科医学,2021,24(3):280-284.
[10] 牟伦盼,蒋建家,张雅萍,等.达格列净与利格列汀对口服降糖药控制不佳的超重或肥胖2型糖尿病患者的疗效和安全性比较[J].中华糖尿病杂志,2019,11(3):190-195.
[11] Tomkins M,Lawless S,Martin-Grace J,et al.Diagnosis and Management of Central Diabetes Insipidus in Adults[J].J Clin Endocrinol Metab.2022,107(10):2701-2715.
[12] 涂晶晶,唐建东,张维,等.达格列净联合甘精胰岛素及门冬胰岛素对2型糖尿病血糖控制不佳患者血糖波动的影响[J].中国老年学杂志,2020,40(10):2044-2047.
[13] 李萌曦,孟凡东,李伟.短期内达格列净片联合胰岛素强化方案对血糖控制不佳的2型糖尿病患者血糖波动的影响研究[J].世界临床药物,2020,41(11):880-885,890.
[14] 严佳栋,钱震宇,钱佳瑜.达格列净片联合胰岛素治疗单用胰岛素血糖控制不佳2型糖尿病患者的临床疗效[J].中国药物经济学,2020,15(12):51-53,61.
[15] 陈建伟,阮娟娟,魏霞.门冬胰岛素30联合维格列汀治疗二甲双胍血糖控制效果不佳的2型糖尿病患者的临床效果分析[J].内科,2022,17(1):32-35.